Trial Profile

A Prospective Study to Evaluate the Efficacy and Safety of MZL-IPI Risk-adapted Targeted Therapy in Patients With Untreated Marginal Zone B-cell Lymphoma

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 24 Jun 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Obinutuzumab (Primary) ; Orelabrutinib (Primary) ; Lenalidomide
Indications Marginal zone B-cell lymphoma
Focus Therapeutic Use
Acronyms MAGIC

Most Recent Events

15 Jun 2026 According to an InnoCare Pharma media release, data from the trial were presented at the European Hematology Association (EHA) 2026 Congress.
15 Jun 2026 Results presented in the InnoCare Pharma Media Release
24 Mar 2026 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com